This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline durin
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review
โ Scribed by Yun-Fan Liaw
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 164 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
This clinically relevant review focuses on recent findings concerning hepatitis B surface antigen (HBsAg) quantitation in untreated patients and treated patients with chronic hepatitis B. Recent studies and emerging data have shown that both HBsAg and hepatitis B virus (HBV) DNA levels decline during the natural course of a chronic HBV infection; they are lowest in the inactive phase, which is also characterized by the highest HBsAg/HBV DNA ratio. It has been demonstrated that the combined use of HBsAg and HBV DNA levels might help in the identification of true inactive carriers with high accuracy. Retrospective analyses of HBsAg levels in patients undergoing therapy have suggested a role for HBsAg quantitation in monitoring the response to therapy. In comparison with nucleos(t)ide analogues (NAs), interferon-based therapy results in greater overall declines in serum HBsAg levels. A rapid on-treatment decline in HBsAg levels appears to be predictive of a sustained response. With the aid of HBsAg quantitation, it appears that we can anticipate an individualized approach to tailoring the treatment duration. The proposal of early stopping rules for patients not responding to pegylated interferon (according to a lack of any HBsAg decline) represents a step toward a response-guided approach. The development of stopping rules for patients treated with NAs is desirable for reducing the need for lifelong therapy. However, before stopping rules for antiviral therapy can be applied, we need to learn more about the kinetics of HBsAg declines during the natural history of the infection and as a response to therapy so that we can better define the best timing, the relevant HBsAg cutoff levels, and the best ways to apply these rules in clinical practice.
๐ SIMILAR VOLUMES
In the June 2011 issue of HEPATOLOGY, in the article entitled ''Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review'' (volume 53, pages 2121-2129) the data in Tables 2 and3 are to be corrected as listed below: On page 2124, under the heading '
## Abstract Antibody to hepatitis B surface antigen (HBsAg) (antiโHBs) can exist in patients with chronic hepatitis B virus (HBV) infection. To date, little is known about the association of concurrent HBsAg and antiโHBs (concurrent HBsAg/ antiโHBs) with hepatocellular carcinoma (HCC). The aim of t
## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAgโpositive and HBeAg
This study examined a signal amplification assay, the Invader assay, for the quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in liver biopsies and sera. DNA was extracted from liver biopsy and serum samples were collected from 16 hepatitis B e antigen (HBeAg)-positive
## Abstract A study was conducted during a 1 year followโup to characterize the viral kinetics in hepatitis B e antigen (HBeAg)โpositive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fiftyโseven patients with HBeAgโpositive chronic hep